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Abstract Tumor necrosis factor (TNF) induces osteoclast
differentiation from bone marrow cells in the presence of
macrophage colony-stimulating factor. Treatment of bone
marrow cells with SB203580 but not PD98059 inhibited TNF-
induced osteoclast differentiation. In RAW264 cells which
differentiate into osteoclast-like multinucleated cells by TNF
treatment alone, activation of p38 mitogen-activated protein
(MAP) kinase induced by murine TNF was comparable to and
independent of the receptor activator of necrosis factor-UB
ligand. Moreover, the number of multinucleated osteoclasts
induced by TNF in bone marrow cell cultures derived from p38
MAP kinase gene deficient mice was significantly less than that
from control mice. These results indicate that the p38 MAP
kinase pathway plays a crucial role in TNF-mediated osteoclast
differentiation. ß 2000 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights re-
served.
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1. Introduction
Osteoclasts which di¡erentiate from hematopoietic myeloid
precursors of monocyte/macrophage lineage, play pivotal
roles in bone morphogenesis, remodeling, and resorption in
concert with other supporting cells such as osteoblasts and
stromal cells [1^6].
The receptor activator of necrosis factor (NF)-UB ligand
(RANKL) [7], a member of tumor necrosis factor (TNF) li-
gand family, is highly expressed in supporting cells and di-
rectly induces the di¡erentiation and maturation of osteoclasts
[8]. It has been shown that mutant mice disrupted with either
RANKL [9] or its receptor RANK [10] revealed severe osteo-
petrosis, indicating that the RANKL^RANK signaling system
plays an essential role in the osteoclast di¡erentiation. In our
recent work, we investigated the signal transduction mecha-
nism of RANKL-induced osteoclastogenesis and found that
the p38 mitogen-activated protein (MAP) kinase signaling
pathway plays an important role in the di¡erentiation of
bone marrow cells into osteoclast-like multinucleated cells
[11].
TNF, a monocyte/macrophage-derived cytokine, was origi-
nally identi¢ed as a factor with anti-tumor activity in vitro
and in vivo, but is now known to be implicated in diverse
biological processes including in£ammation, immunoregula-
tion, anti-viral defense, endotoxic shock, angiogenesis, and
mitogenesis [12,13]. Moreover, it has been reported that in
the presence of macrophage colony-stimulating factor (M-
CSF), TNF directly acts on osteoclast progenitors and in-
duces osteoclast di¡erentiation [14^16]. Since chronic in£am-
matory diseases such as rheumatoid arthritis and periodontal
diseases are associated with the accumulation of TNF, it is
generally believed that TNF is one of the mediators of local
bone destruction seen in these diseases [17]. In addition, it has
been reported that the injection of anti-TNF monoclonal anti-
body is e¡ective for the improvement of rheumatoid arthri-
tis.[17,18]. Since osteoclasts have been identi¢ed in tissue sec-
tions from sites of bone erosion in rheumatoid arthritis and
animal models of in£ammatory arthritis [19], it is essential to
elucidate the mechanism of TNF action on osteoclasts for the
development of reagents which improve the diseases.
In the current study, we have investigated the signal trans-
duction mechanism of TNF-mediated osteoclastogenesis. Our
data reveal that activation of p38 MAP kinase plays a pivotal
role in TNF-induced osteoclast di¡erentiation.
2. Materials and methods
2.1. Materials
Recombinant murine TNF-K (mTNF) was purchased from RpD
systems Inc. (Minneapolis, MN, USA) and recombinant soluble hu-
man RANKL (sRANKL) from Peprotech EC Ltd. (London, UK).
Murine M-CSF and recombinant human interleukin-1L (IL-1L) from
Genzyme (Cambridge, MA, USA). Polyclonal antibodies against p38
MAP kinase and phosphorylated p38 MAP kinase (Thr180/Tyr182) and
GST^ATF2 protein were purchased from New England Biolabs Inc.
(NEB, Beverly, MA, USA). The polyclonal anti-MAPKAP kinase-2
and MAPKAP kinase substrate peptide were obtained from Upstate
Biotechnology Inc. (Lake Placid, NY, USA). Recombinant mouse
osteoprotegerin (OPG)-Fc chimera protein was from RpD systems
Inc. (Minneapolis, MN, USA). SB203580 and PD98059 were pur-
chased from Calbiochem Corp. (La Jolla, CA, USA) and NEB, re-
spectively.
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2.2. Cell culture
Bone marrow cells were prepared by removing femurs from 6^8-
week-old mice and £ushing the bone marrow cavity with RPMI-1640
(Life Technologies Inc. Gaithersburg, MD, USA) containing 10%
fetal bovine serum (FBS) (JRH Biosciences, Lenexa, KS, USA), 100
Wg/ml kanamycin, 1% non-essential amino acid (NEAA), 1% sodium
pyruvate and 5 WM L-mercaptoethanol [11]. After lysing erythrocytes
with a lysing bu¡er (17 mM Tris, pH 7.65, 0.75% NH4Cl), cells were
seeded at 1.5U106 cells/well (0.5 ml) in 24-well plates in the presence
of M-CSF. After a 3-day culture in a fresh complete medium contain-
ing the appropriate reagents, non-adherent cells were removed from
the culture by pipetting and washing with PBS [15]. Adherent cells
were further incubated for 4 days. Then cells were washed and sub-
jected to a tartrate-resistant acid phosphatase (TRAP) assay (see be-
low).
RAW264 (RIKEN, RCB0535 lot no.008) were grown in MEM
media supplemented with 5% FBS and 1% NEAA. For the TRAP
assay, RAW264 cells were trypsinized and starved for 5 h in serum-
free MEM/NEAA media and then cultured for 5 days in MEM/
NEAA containing 2% FBS and the desired cytokines.
2.3. Osteoclast di¡erentiation assay
Osteoclast formation was measured by quantifying TRAP-positive
cells as described [11]. In brief, adherent cells were ¢xed with 10%
formaldehyde in PBS for 3 min. After treatment with ethanol/acetone
(50:50 v/v) for 1 min, the well surface was air dried and incubated at
room temperature in an acetate bu¡er (0.1 M sodium acetate, pH 5.0)
containing 0.01% naphthol AS-MX phosphate (Sigma, St Louis, MO,
USA) and 0.03% fast red violet LB salt (Sigma) in the presence of 50
mM sodium tartrate. Osteoclast-like TRAP-positive cells in each well
were scored by counting the number of TRAP-positive mononuclear
or multinucleated cells containing three or more nuclei.
2.4. Western blot analysis
Immunoblots and immunoprecipitations were performed as de-
scribed [20,21]. In brief, cells were lysed in a lysis bu¡er (20 mM
HEPES, pH 7.4, 2 mM EGTA, 50 mM L-glycerophosphate, 0.1%
Triton X-100, 10% glycerol, 1 mM dithiothreitol (DTT), 1 Wg/ml
leupeptin, 5 Wg/ml aprotinin, 1 mM phenylmethylsulfonyl £uoride,
1 mM sodium orthovanadate). Whole cell extracts (WCEs) sonicated
for 5 s four times were prepared by centrifugation at 10 000Ug for 15
min at 4‡C. WCEs (30 Wg) were electrophoresed on a 10% SDS^poly-
acrylamide gel and blotted onto polyvinylidene di£uoride membranes.
Immunoblot detection was performed with the corresponding anti-
bodies using a ECL detection kit (Amersham Pharmacia Biotech,
Buckinghamshire, UK).
2.5. Protein kinase assays
p38 MAP kinase activity was measured in an immune complex
kinase assay. Phosphorylated p38 MAP kinase was immunoprecipi-
tated by incubation with anti-phosphorylated p38 (pp38) monoclonal
antibody immobilized on agarose beads (anti-pp38 Ab-agarose). After
16 h of incubation at 4‡C, the immunoprecipitates were collected,
washed twice with WCE lysis bu¡er, and then twice with a kinase
bu¡er (25 mM Tris, pH 7.5, 5 mM L-glycerophosphate, 2 mM DTT,
0.1 mM sodium orthovanadate, 10 mM MgCl2). immunoprecipitates
of anti-pp38 Ab-agarose were mixed with 2 Wg of GST fused to ATF2
(GST^ATF2) protein as a substrate and 200 WM ATP in 50 Wl of
kinase bu¡er. Then the reaction mixtures were further incubated for
30 min at 30‡C. The kinase reaction was terminated by boiling in an
appropriate volume of SDS sample bu¡er. The phosphorylated GST^
ATF2 was detected by Western blot analysis with anti-phosphorylated
ATF2 polyclonal antibody (NEB).
For MAPKAP kinase-2 assay, immunoprecipitates were incubated
for 30 min at 30‡C with 100 WM of ATP and 1 WCi of [Q-32P]ATP in
30 Wl of the kinase bu¡er (50 mM L-glycerophosphate, pH 7.0, 0.1
mM EDTA, 10 mM magnesium acetate, and 0.1 mM Na3VO4). The
reactions were terminated by adding 10 Wl of 1% orthophosphoric
acid containing 1 mM ATP and 1% BSA. An aliquot (25 Wl) was
then spotted onto P81 phosphocellulose ¢lters and radioactivity in-
corporated into the substrate peptide was determined by liquid scin-
tillation spectrometry after washing the ¢lter ¢ve times in 0.75% phos-
phoric acid.
2.6. p38 MAP kinase de¢cient mice
p38 MAP kinase de¢cient mice were generated by gene targeting
previously and backcrossed to C57BL/6J strain mice for four or ¢ve
generations [22]. Genotyping was carried out by PCR using DNA
templates prepared from mouse tails.
3. Results and discussion
It is recently reported that the treatment of bone marrow
cells with M-CSF and TNF induces osteoclastogenesis [14^
16]. It is also suggested that the intracellular signal through
TNF is independent of that of RANKL since TNF and
sRANKL synergistically induce osteoclastogenesis from
bone marrow macrophages in the presence of M-CSF [14].
To test the possibility, we compared the morphological
changes of murine bone marrow cell-derived adherent cells
treated either with mTNF or sRANKL in the presence of
M-CSF (Fig. 1). As shown previously [11], sRANKL (100
ng/ml) induced both TRAP-positive mononuclear and multi-
nucleated cells in the presence of M-CSF. Comparable induc-
tion of TRAP-positive mononuclear cells was observed when
Fig. 1. Cytokine-induced formation of osteoclast-like mononuclear
(A) and multinucleated (B) cells from murine bone marrow cells ob-
tained from ddY mice. Bone marrow adherent cells were incubated
for 7 days with no addition, M-CSF (20 ng/ml), M-CSF and
sRANKL (100 ng/ml), M-CSF and mTNF (100 ng/ml), and M-CSF
and IL-1L (100 ng/ml). The cells were treated with SB203880 (5 WM)
30 min prior to the addition of cytokines. After incubation, cells
were subjected to the TRAP assay as described in Section 2. Cells
containing three or more nuclei were scored as multinucleated cells
in (B). Results represent the mean þ S.D. of triplicate determina-
tions.
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cells were treated with mTNF and M-CSF. On the other
hand, mTNF (100 ng/ml) induced TRAP-positive multi-
nucleated cells less e⁄ciently and about 35% decrease in the
appearance of the cells was observed. IL-1L had little e¡ect on
the induction of TRAP-positive cells in our assay system.
We then examined the e¡ect of SB203580, a speci¢c inhib-
itor of p38 MAP kinase [23^25], on the cytokine-induced dif-
ferentiation of osteoclasts. As shown in Fig. 1, treatment of
bone marrow cells with SB203580 inhibited the cytokine-in-
duced appearance of both TRAP-positive mononuclear and
multinucleated cells almost completely. In contrast, PD98059,
a speci¢c inhibitor of MAPK/ERK kinase had no e¡ect on
the cytokine-induced osteoclastogenesis. These results strongly
suggest that the mTNF-mediated signal transduction pathway
in osteoclastogenesis shares, at least in part, the p38 MAP
kinase signaling pathway with that mediated by sRANKL.
However, it was reported that while RANKL could mediate
the functional maturation of osteoclasts, IL-1 was required
for the TNF-mediated maturation of the cells [14,15]. These
results suggest that activation of p38 MAP kinase is required
for the early stage of osteoclast di¡erentiation.
To examine the relationship between osteoclast di¡erentia-
tion and p38 MAP kinase activation, we employed the murine
monocyte cell line, RAW264, since this cell line is known to
di¡erentiate into osteoclast-like multinucleated cells when
treated with sRANKL [11,26]. M-CSF is not required for
the di¡erentiation. Fig. 2 shows the e¡ect of mTNF on the
morphological changes of RAW264 cells. mTNF induced the
di¡erentiation into TPAP-positive multinucleated cells in the
absence of M-CSF. mTNF induced TPAP-positive multi-
Fig. 2. Inhibition of mTNF-induced RAW264 cell di¡erentiation by SB203580. A: RAW264 cells were seeded at 1U104 cells per well in 96-
well plates and incubated for 6 days with: no addition (a), mTNF (100 ng/ml) (b), mTNF (100 ng/ml) and SB203580 (2.5 WM) (c). After incu-
bation, cells were subjected to the TRAP assay as described in Section 2. Scale bar = 100 Wm. B: Quantitative analysis of mTNF-induced di¡er-
entiation of RAW264 cells into TRAP-positive multinucleated cells. The cells were incubated with various concentrations of mTNF in the pres-
ence or absence of inhibitors as indicated.
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nucleated cells in a dose-dependent manner (Fig. 2B). How-
ever, when compared with sRANKL, it was slightly less. As
expected, SB203580 but not PD98059 inhibited the appear-
ance of TRAP-positive multinucleated cells almost com-
pletely.
Fig. 3 shows the kinetic analysis of p38 MAP kinase acti-
vation induced by mTNF. Phosphorylated p38 MAP kinase
was detectable at least within 15 min, reached a plateau at 30
min after addition of mTNF and declined to a basal level in
up to 2 h. We also measured the in vitro kinase activity em-
ploying GST^ATF2 fusion protein as a substrate and found
that the kinase activity correlated well with the phosphoryla-
tion of p38 MAP kinase. On the other hand, total amounts of
the p38 MAP kinase protein were not a¡ected by mTNF
treatment.
To con¢rm the in vivo activation of p38 MAP kinase by
mTNF, we next measured the activation of MAPKAP kinase-
2, a speci¢c physiological substrate of p38 MAP kinase (Fig.
4) As in the case of sRANKL, activation of MAPKAP ki-
nase-2 was ¢rst detectable at 15 min and reached to the max-
imum level at 60 min after addition of mTNF. As expected,
pretreatment of SB203580 but not PD98059 inhibited the
mTNF-stimulated MAPKAP kinase-2 in a dose-dependent
manner with IC50 being 0.34 WM.
Fig. 4C shows the e¡ect of OPG, a decoy receptor for
RANKL [27], which inhibits the RANKL- but not TNF-in-
duced osteoclastogenesis [14,15]. While OPG inhibited the
RANKL-induced MAPKAP kinase-2 activation in a dose-de-
pendent manner, it had no e¡ect on that induced by mTNF,
indicating that mTNF activated p38 MAP kinase independ-
ently of RANKL and mTNF-induced RANKL, if any, had
little contribution to the p38 MAP kinase activation.
To further address the role of p38 MAP kinase in TNF-
induced osteoclastogenesis, we next examined the osteoclasto-
genic e¡ect of mTNF on bone marrow cells prepared from
p38 MAP kinase de¢cient mice [22]. Since the null mutation
of the gene is embryonic lethal, we prepared the cells from
heterogeneously gene disrupted (p38=3) mice. It was shown
that in comparison to wild type mice, the expression level of
p38 MAP kinase was signi¢cantly reduced in p38=3 mice
[22]. As shown in Fig. 5, repeated experiments indicated
that number of mTNF-induced TRAP-positive multinucleated
cells derived from p38=3 mice was signi¢cantly less than that
from wild type littermates. On average, about 28% decrease in
Fig. 3. Activation of p38 MAP kinase in RAW264 cells treated
with mTNF. RAW264 cells (106 cells/culture) were treated with 100
ng/ml mTNF for the indicated times and then cells were lysed. Cell
lysates (30 Wg) were resolved by SDS^PAGE and immunoblotted
with anti-pp38 MAP kinase (upper panel), or anti-p38 MAP kinase
antibody (lower panel). In the middle panel, p38 MAP kinase activ-
ity was measured using GST^ATF2 protein as a substrate.
C
Fig. 4. Activation of MAPKAP kinase-2 in RAW264 cells treated
with sRANKL. A: RAW264 cells were treated with mTNF (100 ng/
ml) for indicated times in the presence (closed circle) or absence
(open circle) of SB203580 (5 WM) and cell lysates were immunopre-
cipitated with anti-MAPKAP kinase-2 antibody. B: Inhibition of
MAPKAP kinase-2 activity by SB203580. RAW264 cells were pre-
treated with various concentrations of SB203580 for 30 min. Cells
were then treated with 100 ng/ml mTNF, further incubated for 15
min and immunoprecipitated with anti-MAPKAP kinase-2 antibody.
C: Inhibition of MAPKAP kinase-2 activity by OPG. RAW264
cells were treated either with mTNF (100 ng/ml) or sRANKL (100
ng/ml) in the presence of various concentrations of OPG for 15 min
and immunoprecipitated with anti-MAPKAP kinase-2 antibody. Re-
sults represent the mean þ S.D. of triplicate determinations.
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the appearance of TRAP-positive multinucleated cells was
observed. These results suggest that the decreased expression
of p38 MAP kinase in bone marrow cells caused the decrease
in mTNF-mediated osteoclastogenesis. Similar results were
obtained in RANKL-induced osteoclast di¡erentiation (data
not shown).
In this paper, we have examined the signal transduction
mechanism of TNF-induced osteoclastogenesis. As in the
case of sRANKL, mTNF-induced osteoclastogenesis was in-
hibited by SB203580, indicating for the ¢rst time that the p38
MAP kinase signaling pathway plays a pivotal role in TNF-
mediated di¡erentiation of bone marrow cells into osteoclasts.
Decrease in the number of mTNF-induced osteoclasts derived
from bone marrow cells of p38=3 mice support the notion.
According to the sequential phenotype progression model,
osteoclastogenesis is divided into several stages [2^6,28]. The
model includes the appearance of mononuclear osteoclasts,
the fusion process prior to mulitinucleated osteoclast forma-
tion, and the osteoclast maturation processes. It was shown
that while RANKL could mediate the functional maturation
of mulitinucleated osteoclasts, in TNF-mediated osteoclasto-
genesis, IL-1 is required for the maturation [14,15]. Moreover,
in our preliminary experiments, although human TNF in-
duced considerable TRAP-positive mononuclear cells, signi¢-
cant decrease in the appearance of TRAP-positive multi-
nucleated cells was observed when compared with mTNF,
suggesting that at least two signals were required for the dif-
ferentiation of bone marrow cells into TRAP-positive multi-
nucleated cells [14^16]. It is conceivable that while signal
through TNF receptor 1 alone is su⁄cient for the induction
of TRAP-positive mononuclear cells, that through TNF re-
ceptor 2 is also required for the di¡erentiation into multinu-
clear osteoclasts [14,15]. In this connection, it has been sug-
gested that c-Jun N-terminal kinases (JNKs) play important
roles in osteoclastogenesis [29^31]. Phosphorylation of JNKs
was clearly detectable in RAW264 cells after treatment with
mTNF (data not shown). To understand the signal transduc-
tion mechanisms of osteoclastogenesis exactly, we are now
trying to elucidate the roles of these two receptors in detail.
It has been reported that TNF plays pivotal roles in the
local bone destruction that is associated with chronic in£am-
matory diseases such as rheumatoid arthritis. Our present
data may facilitate the development of new reagents which
improve these diseases.
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